



## Cabaletta Bio to Present at the Evercore ISI 2nd Annual HealthCONx Conference

November 26, 2019

PHILADELPHIA, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer and Co-founder, will present at the Evercore ISI 2<sup>nd</sup> Annual HealthCONx Conference on Wednesday, December 4, 2019, at 9:50 a.m. EST. The conference will be held at the Four Seasons Hotel in Boston, MA.

A live audio webcast of the presentation can be accessed through the Events & Presentations section of the Company's website at [investors.cabalettabio.com](http://investors.cabalettabio.com). An archived replay of the webcast will be available on the Company's website for approximately 90 days following the live presentation.

### About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta's proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. Cabaletta's lead product candidate is based on the Chimeric Antigen Receptor (CAR) T cell technology developed at the University of Pennsylvania (Penn) that resulted in the first commercially-available CAR T cell products for the treatment of B cell cancers. Cabaletta has an exclusive global licensing agreement and multiple sponsored research agreements with the University of Pennsylvania to develop the CAAR T technology to treat B cell-mediated autoimmune diseases. The Company's lead product candidate is being studied as a potential treatment for a prototypical B cell-mediated autoimmune disease, mucosal pemphigus vulgaris. For more information, visit [www.cabalettabio.com](http://www.cabalettabio.com).

### Investors and Contacts:

Anup Marda  
Chief Financial Officer  
[investors@cabalettabio.com](mailto:investors@cabalettabio.com)

### Media:

Ryo Imai / Robert Flamm, Ph.D.  
212-213-0006, ext. 315 / ext. 364  
[rimai@burnsmc.com](mailto:rimai@burnsmc.com) / [rflamm@burnsmc.com](mailto:rflamm@burnsmc.com)



Source: Cabaletta Bio